Bourla认为每月一次给药将受到强烈偏好,使辉瑞既能争取新增GLP-1患者,也能转化维持期的每周制剂患者。
我们相信人们会非常偏好每月一次的产品,这不仅让我们能在每位新增GLP-1患者中获得可观份额,还能把处于维持期的每周制剂患者转到我们的每月制剂。原文 (en)
We believe that uh for products that they are monthly there will be a huge preference from people and that will allow us not only to gain good market share of every new patient that is going into the GLP1s but also we can switch patients that they are already on their maintenance phase in the weekly products into our monthly.